TRCT
ACUR

Tower Research Capital (TRC)’s Acura Pharmaceuticals ACUR Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-747
Closed -$1K – 4903
2016
Q3 		$1K Sell
747
-1,515
-67% -$2.68K ﹤0.01% 3499
2016
Q2 		$4K Buy
2,262
+1,687
+293% +$4.35K ﹤0.01% 3617
2016
Q1 		$2K Sell
575
-161
-22% -$342 ﹤0.01% 3561
2015
Q4 		$2K Sell
736
-3,956
-84% -$9.62K ﹤0.01% 3932
2015
Q3 		$11K Buy
+4,692
New +$16K ﹤0.01% 2278
2014
Q4 		– Sell
-741
Closed -$3K – 5203
2014
Q3 		$3K Buy
741
+671
+959% +$3.15K ﹤0.01% 3693
2014
Q2 		$0 Sell
70
-833
-92% -$5.05K ﹤0.01% 5067
2014
Q1 		$7K Sell
903
-6,659
-88% -$57.8K ﹤0.01% 3028
2013
Q4 		$63K Buy
7,562
+7,106
+1,558% +$60K 0.01% 1206
2013
Q3 		$4K Sell
456
-846
-65% -$7.48K ﹤0.01% 3866
2013
Q2 		$12K Buy
+1,302
New +$14.7K ﹤0.01% 2233

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tower Research Capital (TRC)'s ACUR Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of Acura Pharmaceuticals (ACUR) in Q4 2016, closing a stake of 747 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in ACUR in Q2 2013 and held it in 11 quarters. The position peaked at $63K in Q4 2013. 22 funds tracked by Wall St. Rank hold ACUR as of Q4 2016.

  • Tower Research Capital (TRC) reported no remaining Acura Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 747 Acura Pharmaceuticals shares in Q4 2016, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Acura Pharmaceuticals position peaked at $63K in Q4 2013.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.